Head-to-head · Cost-Efficiency Index
Aquivia Health vs MEDVi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Aquivia Health
Shoppers who want clinician-reviewed compounded GLP-1s with the option to move up to brand-name Ozempic or Zepbound.
Visit Aquivia HealthMEDVi
Shoppers who want compounded semaglutide with no contract and are budgeting on the $299 refill price, not the first-month sale price.
Visit MEDViThe verdict
Aquivia Health and MEDVi tie on the Cost-Efficiency Index at 62/100, so neither wins outright on the numbers, so choose on fit. Aquivia Health: Shoppers who want clinician-reviewed compounded GLP-1s with the option to move up to brand-name Ozempic or Zepbound. MEDVi: Shoppers who want compounded semaglutide with no contract and are budgeting on the $299 refill price, not the first-month sale price.
Worth knowing either way: CoreAge Rx is one of our partners and leads our leaderboard, where partners are listed first (Cost-Efficiency Index 94/100). See how it stacks up: CoreAge Rx vs Aquivia Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Aquivia Health | MEDVi |
|---|---|---|
| Cost-Efficiency Index | 62/100 | 62/100 |
| Semaglutide / mo | $149/mo | $299/moMonth-to-month refill price; first month $179, compounded |
| Tirzepatide / mo | $179/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,788 | $3,588 |
| Tirzepatide / yr (modeled) | $2,148 | — |
| Coverage | Coverage not published | Not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Yes |
| Rank here | #264 | #268 |
Aquivia Health
62/100Where the value is
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
The tradeoffs
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
MEDVi
62/100Where the value is
- The FAQ states both numbers plainly: $179 for the first month and refills locked in at $299, covering the provider review, the medication and shipping
- No contract; you can cancel at any time by email or through the patient portal chat
- Names its partner pharmacies (Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding) and the medical groups behind its providers
The tradeoffs
- The $179 headline is a first-month "FALL Sale" price; every refill after that is $299
- Cancellation must reach support at least 72 hours before your next billing date, and monthly charges are never refunded once the month has started
Regulatory note: the FDA issued a warning letter to MEDVi, LLC dba MEDVi in February 2026. We still list and link to MEDVi; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.